TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31102257
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg q2w
Study: 26883438
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous infusion of ponesimod over 3 hours
Study: 26883438
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral administration of ponesimod
Study: 24705568
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy and/or contingency management (12-week randomized controlled trial)
Study: 18486273
Drug: Weekly vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vinorelbine chemotherapy (30 mg/m² for 6 weeks)
Study: 17728357
Drug: High-dose rhEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhEPO (48,000 IU)
Study: 17728357
Drug: Low-dose rhEPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhEPO (8000 IU)
Study: 17728357
Drug: Drug-naïve Parkinson
Normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-naïve Parkinson patients (48,000 IU)
Study: 11589674
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (Andropatch 2.5 mg patches, 1-2 patches per day)
Study: 9400916
Drug: Lispro human
Normalized name: INSULIN LISPRO HUMAN 100 UNIT/ML HUMALOG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro human insulin (2.0 mU kg(‐1) min(‐1))
Study: 9400916
Drug: Human soluble
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human soluble insulin (HS) (2.0 mU kg(‐1) min(‐1))
Study: 7950410
Drug: Hyperosmolar agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar agent (glucose solution)
Study: 3298379
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg azelastine
Study: 3298379
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg azelastine
Study: 3298379
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg azelastine
Study: 27768797
Drug: IOP-reducing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP-reducing therapy
Study: 24108409
Drug: vestipitant (GW597599)
Normalized name: Vestipitant
DrugBank: Vestipitant (DB11949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vestipitant (GW597599) 15 mg
Study: 24108409
Drug: alprazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam 0.75 mg
Study: 24108409
Drug: vofopitant (GR205171)
Normalized name: Vofopitant
DrugBank: Vofopitant (DB12436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vofopitant (GR205171) 25 mg
Study: 22594907
Drug: Bisoprolol/hydrochlorothiazide 5/6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol/hydrochlorothiazide 5/6.25 mg (R)
Study: 22594907
Drug: Amlodipine/valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/160 mg (E)
Study: 17436336
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation T
Study: 17436336
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation R
Study: 15872125
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron plus placebo (group H-O)
Study: 15872125
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron plus 8 mg dexamethasone (group H-OD)
Study: 15872125
Drug: None (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: None (group L)
Study: 12373420
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg delta(9)-THC
Study: 12373420
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg delta(9)-THC
Study: 2650578
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg tid orally)
Study: 2650578
Drug: Pentoxifylline and
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline and Acenocoumarol (combined treatment)
Study: 31116270
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) using 20 ml of 0.25% levobupivacaine (ACB-L group)
Study: 31116270
Drug: Periarticular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration using 40 ml (0.125 mg) of levobupivacaine (PAI-L group)
Study: 23244247
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg/day for 7 days/month followed by Lactobacillus casei for 7 days
Study: 23244247
Drug: Antibiotic followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic followed by short chain fructo-oligosaccharides
Study: 9737127
Drug: Umbilical vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical vein injection of 20 units of oxytocin diluted to 20 ml with normal saline
Study: 9737127
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20 ml
Study: 8062355
Drug: Acetaminophen 400
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 400 mg-codeine 25 mg combination (ACC)
Study: 8062355
Drug: Aspirin 1000
Normalized name: aspirin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1000 mg (A)
Study: 2522062
Drug: Intranasal leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal leuprolide 1.6 mg/day
Study: 2522062
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg/day
Study: 30617950
Drug: Synbiotics (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (15 g of prebiotics, 5 g of probiotic powder containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA‐6, Bifidobacterium lactis BIA‐6, and Bifidobacterium longum LAF‐5)
Study: 30617950
Drug: Probiotics (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (5 g probiotics with 15 g of maltodextrin as placebo)
Study: 30634880
Drug: Local lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local lidocaine spray (LS)
Study: 28899222
Drug: Sotagliflozin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin (400 mg per day)
Study: 24902822
Drug: Individual adolescent-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual adolescent-focused therapy (AFT)
Study: 22051208
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg, single oral dose)
Study: 15349687
Drug: Tripterygium hypoglaucum
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium hypoglaucum hutch tablet
Study: 11020002
Drug: alpha2b interferon
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily) for 12 months
Study: 11020002
Drug: alpha2b interferon
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily) for 6 months
Study: 11020002
Drug: alpha2b interferon
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha2b interferon (6 MU tiw) plus ribavirin (1000-1200 mg daily)
Study: 7829282
Drug: Weekly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly group therapy session in the aftercare clinic
Study: 29533729
Drug: 6-mm dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm dental implants
Study: 29533729
Drug: 10-mm dental
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mm dental implants
Study: 29533729
Drug: Implant survival
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant survival rates
Study: 26222435
Drug: Crinone vaginal
Normalized name: Crinone Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone vaginal progesterone gel (90 mg/d)
Study: 26222435
Drug: Intramuscularly injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly injected progesterone (40 mg/d)
Study: 23743437
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% preservative-free ophthalmic solution
Study: 23743437
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% ophthalmic solution (Lumigan)
Study: 20639714
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (40 mg/kg/day for 3 months)
Study: 20639714
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments for FTT (Control)
Study: 17722305
Drug: Antivir (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivir (test formulation)
Study: 17722305
Drug: Retrovir (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrovir (reference formulation)
Study: 12680737
Drug: Lorazepam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.0 mg)
Study: 11106311
Drug: Flunitrazepam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1.0 mg)
Study: 18241756
Drug: Heparin-bonded expanded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft
Study: 6336824
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (pure oxygen)
Study: 6336824
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (10% oxygen and 90% nitrogen)
Study: 23115621
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (Gardasil™) - Dose 1
Study: 12842242
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg once daily
Study: 12842242
Drug: Eplerenone 100
Normalized name: eplerenone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 100 mg once daily
Study: 12160194
Drug: Eplerenone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 400 mg once daily
Study: 21986283
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg twice daily
Study: 12160194
Drug: Eplerenone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 200 mg twice daily
Study: 12160194
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg twice daily
Study: 10466981
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (ivermectin and albendazole)
Study: 2090474
Drug: Maintenance Dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Dose (MD)
Study: 2090474
Drug: Twice the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice the Maintenance Dose (MDx2)
Study: 31165191
Drug: Burosumab 1
Normalized name: Burosumab 10 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab 1 mg/kg every 4 weeks
Study: 21134775
Drug: Linezolid (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (IV or oral)
Study: 19136101
Drug: 1 injection
Normalized name: vitamin K1 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of bupivacaine and triamcinolone
Study: 19136101
Drug: 2 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections of bupivacaine and triamcinolone
Study: 18978166
Drug: Muesli with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muesli with 4 g oat beta-glucan
Study: 10465130
Drug: Cefepime monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime monotherapy
Study: 10465130
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with trimethoprim/sulfamethoxazole plus amikacin (TMP/SMZ plus AMI)
Study: 1697490
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day for 4 weeks
Study: 1697490
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1 g/day for 4 weeks
Study: 1107506
Drug: 0.1 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/m2 of synthetic luteinizing hormone‐releasing hormone
Study: 21515226
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lumiracoxib
Study: 18070204
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 6% active complex antiageing cream
Study: 18070204
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of all-trans retinoic acid (RA)
Study: 18070204
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 2% active complex antiageing cream
Study: 18070204
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of basic moisturizer
Study: 11043842
Drug: Sodium clodronate
Normalized name: Sodium clodronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium clodronate 1600 mg daily p.o. (arm A)
Study: 1735269
Drug: Allergen (Ag)
Normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allergen (Ag) inhalation
Study: 18622283
Drug: Reduced TAC
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced TAC (target trough level 3.0‐5.9 ng/mL)
Study: 18622283
Drug: Standard TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TAC (target trough level 6.0‐8.9 ng/mL)
Study: 11833837
Drug: Glyburide 15
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide 15 mg/d
Study: 7718549
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (CaCO3 tablet, 300 mg Ca)
Study: 15068414
Drug: Sucralfate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (3 g/day)
Study: 2202200
Drug: Sulglycotide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulglycotide (600 mg/day)
Study: 31378665
Drug: Metabolomic profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolomic profile based on fatty acid metabolism and γ‐glutamyl amino acids
Study: 26994089
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Study: 26994089
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg) with tenofovir disoproxil/emtricitabine (245/200 mg)
Study: 29091217
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (400/100 mg)
Study: 26994089
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg)
Study: 25069759
Drug: IFN α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN α‐2b therapy for ET patients with JAK2V617F(+).
Study: 25069759
Drug: IFN α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN α‐2b therapy for PV patients with JAK2V617F(+).
Study: 25069759
Drug: IFN α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN α‐2b therapy for MPDs patients.
Study: 25069759
Drug: IFN α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN α‐2b therapy.
Study: 22140200
Drug: Immediate group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate group (2 hours of inpatient physical and occupational therapy focusing on coordination, balance, and ADLs for 4 weeks)
Study: 17934240
Drug: Royal jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal jelly (RJ) supplementation at 6 g per day for 4 weeks
Study: 7615227
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg per OS three times during the day before the procedure and one 10‐mg dose on the morning of the procedure)
Study: 2116160
Drug: Atenolol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (4 mg i.v.)
Study: 2116160
Drug: Buccal nitroglycerin
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerin (5 mg)
Study: 31356561
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 480 mg/min (group A)
Study: 31356561
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 240 mg/min (group B)
Study: 31356561
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 120 mg/min (group C)
Study: 26062881
Drug: Dual treatment
Normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus lamivudine (300 mg once daily)
Study: 26062881
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment with atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus two nucleos(t)ide reverse transcriptase inhibitors
Study: 26062880
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment
Study: 16415894
Drug: ATG (Thymoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (Thymoglobulin 2 mg/kg x 3 days)
Study: 16415894
Drug: Campath (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath (30 mg x 3 days subcutaneously)
Study: 16415894
Drug: Campath (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath (30 mg once)
Study: 11369502
Drug: alpha-tocopherol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (400 IU dL-alpha-tocopherol daily)
Study: 10717770
Drug: Natural light/dark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural light/dark cycle (L/Dc) exposure through windows
Study: 20697941
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Xiaozheng Zhitong Paste (XZP) in addition to basic therapy (3L analgesia)
Study: 20697941
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (3L analgesia) without XZP
Study: 20697941
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of XZP
Study: 15787815
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 50 mg daily or 100 mg for 10 days per month if premenopausal
Study: 15787815
Drug: Oral antiandrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiandrogens (combined results of spironolactone and cyproterone acetate)
Study: 15787815
Drug: Oral antiandrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiandrogens
Study: 11994342
Drug: ARG plus
Normalized name: Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ARG plus L-DOPA test
Study: 11994342
Drug: L-DOPA test
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA test
Study: 2653414
Drug: Progestational agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestational agents
Study: 24811578
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine every day for 1 month
Study: 24811578
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil on demand 2 hours before intercourse
Study: 15290412
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg and 3 mg
Study: 11742045
Drug: Supportive‐expressive group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive‐expressive group therapy
Study: 8493295
Drug: Electroencephalographic (EEG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroencephalographic (EEG) sleep assessments after successful treatment
Study: 26492477
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midodrine hydrochloride
Study: 21436319
Drug: Corticosteroids +
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids + antifungal
Study: 21436319
Drug: Antifungal only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal only
Study: 18297267
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injections (IB) of meropenem 1 g every 12 h
Study: 18297267
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of meropenem 0.5 g loading dose followed by 2 g over 24 h
Study: 14623657
Drug: Active glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active glyceryl trinitrate transdermal patch
Study: 1642936
Drug: ketorolac trometamol
Normalized name: Ketorolac trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac trometamol 10 mg administered 4‐hourly by intermittent i.m. injection or by continuous i.m. infusion